Pre- and Post-Neoadjuvant Clinicopathological Parameters Can Help in the Prognosis and the Prediction of Response in HER2+ and Triple Negative Breast Cancer
Pons, Laura (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Hernández, Laura (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Urbizu, Aintzane (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Osorio, Paula (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Rodríguez-Martínez, Paula (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Castellà Fernández, Eva (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Muñoz-Mármol, Ana Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Sanz, Carolina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Arnaldo, Laura (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Felip, Eudald (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Quiroga García, Vanesa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Tapia, Gustavo (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Margelí, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Fernández, Pedro Luis (Universitat Autònoma de Barcelona)

Fecha:	2023
Resumen:	HER2+ and triple negative breast cancers are widely known for their aggressiveness, frequent resistance to treatment and poor prognosis. Neoadjuvant management has provided promising results for both subtypes, but there is still a subset of patients with no or low response. Consequently, a non-negligible number of patients is receiving a treatment regimen that might not be adequate. Identification of these patients is essential to avoid overtreatment and provide more effective treatment options. Neoadjuvant treatment (NAT) is one of the most widely used options for HER2+ and triple negative (TN) early breast cancer (BC). Since around half of the patients treated with NAT do not achieve a pathologically complete response (pCR), biomarkers to predict resistance are urgently needed. The correlation of clinicopathological factors with pCR was studied in 150 patients (HER2 = 81; TN = 69) and pre- and post-NAT differences in tumour biomarkers were compared. Low estrogen receptor (ER) expression, high tumour-infiltrating lymphocytes (TILs) and low cT-stage were associated with pCR in HER2+ tumours (p = 0. 022; p = 0. 032 and p = 0. 005, respectively). Furthermore, ER expression was also associated with residual cancer burden (RCB; p = 0. 046) in the HER2+ subtype. Similarly, pre-NAT, low progesterone receptor expression (PR; 1-10%) was associated with higher RCB (p < 0. 001) in TN tumours. Only clinical and pathological T-stage (cpT-stage) had prognostic capacity in HER2+ tumours, whereas pre-NAT cpT-stage and post-NAT TILs had this capacity for the prognosis of TN tumours. We conclude that ER and PR expression may help predict response to NAT in HER2 and TN BC and should be taken into account in residual tumours. Also, changes observed in the phenotype after NAT suggest the need to reevaluate biomarkers in surviving residual tumour cells.
Ayudas:	Instituto de Salud Carlos III PI19/01371 Fundació la Marató de TV3 567/C/2019
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Breast cancer ; Neoadjuvant chemotherapy ; HER2+ ; Triple negative
Publicado en:	Cancers, Vol. 15 Núm. 12 (2023) , p. 1-19 (Articles) , ISSN 2072-6694

DOI: 10.3390/cancers15123068
PMID: 37370679

19 p, 3.7 MB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Artículos > Artículos de investigación
Artículos > Artículos publicados